Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection

被引：1

作者：

Liang, Juan ^{[1
,3
]}

Xu, Xiaojun ^{[1
,3
]}

Chen, Zhenjie ^{[2
]}

Yu, Jia ^{[2
]}

Tang, Yongmin ^{[1
,3
]}

机构：

[1] Zhejiang Univ, Childrens Hosp, Sch Med, Div Hematol Oncol, Hangzhou, Peoples R China

[2] Zhejiang Univ, Dept Pediat Intens Care Unit, Childrens Hosp, Sch Med, Hangzhou, Peoples R China

[3] Pediat Leukemia Diagnost & Therapeut Technol Res, Hangzhou, Peoples R China

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2024年 / 46卷 / 05期

基金：

中国国家自然科学基金;

关键词：

cytokine storm; emapalumab; hemophagocytic lymphohistiocytosis; ruxolitinib; severe infection; CHILDREN;

D O I：

10.1097/MPH.0000000000002856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anti-interferon-gamma monoclonal antibody emapalumab and JAK1/2 inhibitors ruxolitinib have been widely reported for the treatment of hemophagocytic lymphohistiocytosis (HLH) recently. These targeted drugs have fewer side effects and may provide new options for patients with HLH who are refractory to previous treatment or intolerant to chemotherapy. Herein, we reported a case of Epstein-Barr virus-related HLH, which did not respond well to HLH-94 plus ruxolitinib and developed severe fungal infection. The disease was successfully controlled after a combination therapy of emapalumab, ruxolitinib, and dexamethasone.

引用

页码：e360 / e362

页数：3

共 7 条

[1] Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study [J].

Bergsten, Elisabet ;

Horne, AnnaCarin ;

Arico, Maurizio ;

Astigarraga, Itziar ;

Egeler, R. Maarten ;

Filipovich, Alexandra H. ;

Ishii, Eiichi ;

Janka, Gritta ;

Ladisch, Stephan ;

Lehmberg, Kai ;

McClain, Kenneth L. ;

Minkov, Milen ;

Montgomery, Scott ;

Nanduri, Vasanta ;

Rosso, Diego ;

Henter, Jan-Inge .

BLOOD, 2017, 130 (25) :2728-2738

[2] Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis [J].

Locatelli, F. ;

Jordan, M. B. ;

Allen, C. ;

Cesaro, S. ;

Rizzari, C. ;

Rao, A. ;

Degar, B. ;

Garrington, T. P. ;

Sevilla, J. ;

Putti, M. -C. ;

Fagioli, F. ;

Ahlmann, M. ;

Diaz, J. -L. Dapena ;

Henry, M. ;

De Benedetti, F. ;

Grom, A. ;

Lapeyre, G. ;

Jacqmin, P. ;

Ballabio, M. ;

de Min, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19) :1811-1822

[3] Prognostic factors of early death in children with hemophagocytic lymphohistiocytosis [J].

Luo, Ze-Bin ;

Chen, Yuan-Yuan ;

Xu, Xiao-Jun ;

Zhao, Ning ;

Tang, Yong-Min .

CYTOKINE, 2017, 97 :80-85

[4] Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective [J].

Triebwasser, Michael P. ;

Barrett, David M. ;

Bassiri, Hamid ;

Bunin, Nancy ;

Elgarten, Caitlin ;

Freedman, Jason ;

Geera, Abdallah S. ;

Monos, Dimitri ;

Lambert, Michele P. ;

Olson, Timothy ;

Seif, Alix E. ;

Paessler, Michele ;

Petrosa, Whitney ;

Reilly, Anne F. ;

Romberg, Neil ;

Sullivan, Kathleen E. ;

Quinn, Ghazal Z. ;

Behrens, Edward ;

Teachey, David T. .

PEDIATRIC BLOOD & CANCER, 2021, 68 (07)

[5] Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis [J].

Vallurupalli, Mounica ;

Berliner, Nancy .

BLOOD, 2019, 134 (21) :1783-1786

[6] Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report [J].

Yan, Wei-Ling ;

Yang, Shi-Long ;

Zhao, Fen-Ying ;

Xu, Xiao-Jun .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) :222-227

[7] A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis [J].

Zhang, Qing ;

Zhao, Yun-Ze ;

Ma, Hong-Hao ;

Wang, Dong ;

Cui, Lei ;

Li, Wei-Jing ;

Wei, Ang ;

Wang, Chan-Juan ;

Wang, Tian-You ;

Li, Zhi-Gang ;

Zhang, Rui .

BLOOD, 2022, 139 (24) :3493-3504

← 1 →